472 related articles for article (PubMed ID: 25592123)
1. Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom.
Buckle M; Lee A; Mohamed Q; Fletcher E; Sallam A; Healy R; Stratton I; Tufail A; Johnston RL
Eye (Lond); 2015 Mar; 29(3):403-8. PubMed ID: 25592123
[TBL] [Abstract][Full Text] [Related]
2. UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: Incidence of Blindness and Sight Impairment in Ranibizumab-Treated Patients.
Johnston RL; Lee AY; Buckle M; Antcliff R; Bailey C; McKibbin M; Chakravarthy U; Tufail A;
Ophthalmology; 2016 Nov; 123(11):2386-2392. PubMed ID: 27615601
[TBL] [Abstract][Full Text] [Related]
3. Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK.
Keenan TD; Kelly SP; Sallam A; Mohamed Q; Tufail A; Johnston RL
Br J Ophthalmol; 2013 Sep; 97(9):1168-72. PubMed ID: 23813420
[TBL] [Abstract][Full Text] [Related]
4. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group
Ophthalmology; 2014 May; 121(5):1092-101. PubMed ID: 24461586
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK.
Buckle M; Donachie PH; Johnston RL
Br J Ophthalmol; 2016 Feb; 100(2):240-5. PubMed ID: 26124462
[TBL] [Abstract][Full Text] [Related]
6. Visual Impairment and Blindness Avoided with Ranibizumab in Hispanic and Non-Hispanic Whites with Diabetic Macular Edema in the United States.
Varma R; Bressler NM; Doan QV; Danese M; Dolan CM; Lee A; Turpcu A
Ophthalmology; 2015 May; 122(5):982-9. PubMed ID: 25670501
[TBL] [Abstract][Full Text] [Related]
7. UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12.
Lee AY; Lee CS; Butt T; Xing W; Johnston RL; Chakravarthy U; Egan C; Akerele T; McKibbin M; Downey L; Natha S; Bailey C; Khan R; Antcliff R; Varma A; Kumar V; Tsaloumas M; Mandal K; Liew G; Keane PA; Sim D; Bunce C; Tufail A;
Br J Ophthalmol; 2015 Aug; 99(8):1045-50. PubMed ID: 25680619
[TBL] [Abstract][Full Text] [Related]
8. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes.
Zarranz-Ventura J; Liew G; Johnston RL; Xing W; Akerele T; McKibbin M; Downey L; Natha S; Chakravarthy U; Bailey C; Khan R; Antcliff R; Armstrong S; Varma A; Kumar V; Tsaloumas M; Mandal K; Bunce C; Tufail A;
Ophthalmology; 2014 Oct; 121(10):1966-75. PubMed ID: 24953791
[TBL] [Abstract][Full Text] [Related]
9. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.
Arnold JJ; Campain A; Barthelmes D; Simpson JM; Guymer RH; Hunyor AP; McAllister IL; Essex RW; Morlet N; Gillies MC;
Ophthalmology; 2015 Jun; 122(6):1212-9. PubMed ID: 25846847
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
Nguyen CL; Gillies MC; Nguyen V; Daien V; Cohn A; Banerjee G; Arnold J;
Ophthalmology; 2019 May; 126(5):735-742. PubMed ID: 30529685
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
[TBL] [Abstract][Full Text] [Related]
12. Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration.
Campbell JP; Bressler SB; Bressler NM
Arch Ophthalmol; 2012 Jun; 130(6):794-5. PubMed ID: 22801846
[No Abstract] [Full Text] [Related]
13. Clinical and social characteristics associated with reduced visual acuity at presentation in Australian patients with neovascular age-related macular degeneration: a prospective study from a long-term observational data set. The Fight Retinal Blindness! Project.
Nguyen V; Daien V; Guymer RH; McAllister IL; Morlet N; Barthelmes D; Gillies MC
Clin Exp Ophthalmol; 2018 Apr; 46(3):266-274. PubMed ID: 28842956
[TBL] [Abstract][Full Text] [Related]
14. METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Kim LN; Mehta H; Barthelmes D; Nguyen V; Gillies MC
Retina; 2016 Aug; 36(8):1418-31. PubMed ID: 27388744
[TBL] [Abstract][Full Text] [Related]
15. Visual acuity and central retinal thickness: fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care.
Reznicek L; Muhr J; Ulbig M; Kampik A; Mayer WJ; Haritoglou C; Neubauer A; Wolf A
Br J Ophthalmol; 2014 Oct; 98(10):1333-7. PubMed ID: 24903670
[TBL] [Abstract][Full Text] [Related]
16. Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial.
Jaffe GJ; Ciulla TA; Ciardella AP; Devin F; Dugel PU; Eandi CM; Masonson H; Monés J; Pearlman JA; Quaranta-El Maftouhi M; Ricci F; Westby K; Patel SC
Ophthalmology; 2017 Feb; 124(2):224-234. PubMed ID: 28029445
[TBL] [Abstract][Full Text] [Related]
17. Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?
Ross AH; Donachie PH; Sallam A; Stratton IM; Mohamed Q; Scanlon PH; Kirkpatrick JN; Johnston RL
Eye (Lond); 2013 Jan; 27(1):56-64. PubMed ID: 23174752
[TBL] [Abstract][Full Text] [Related]
18. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.
Bressler NM; Chang TS; Varma R; Suñer I; Lee P; Dolan CM; Ward J; Ianchulev T; Fine J
Ophthalmology; 2013 Jan; 120(1):160-8. PubMed ID: 23009891
[TBL] [Abstract][Full Text] [Related]
19. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
[TBL] [Abstract][Full Text] [Related]
20. Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland.
Borooah S; Jeganathan VS; Ambrecht AM; Oladiwura D; Gavin M; Dhillon B; Cackett P
Eye (Lond); 2015 Sep; 29(9):1156-61. PubMed ID: 26043706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
